Kindeva Drug Delivery, a global leader in drug-device combination products, is expanding its production capacity with a new manufacturing line for pressurized metered-dose inhalers (pMDIs) using low-GWP (Global Warming Potential) propellants at its Loughborough, U.K. facility. This new line, expected to be operational in 2026, will handle HFA-152a and HFO-1234ze propellants, which offer GWPs 90% and 99.9% lower than the standard HFA-134a.

Key Investment Details

– Capacity & Launch Date: The new line will supply up to 50 million pMDI units annually, becoming operational in 2026.

– First pMDI Line: Kindeva’s initial pMDI manufacturing line, announced in 2022, is set for completion in late 2024.

– Market Demand: The investment responds to rising customer demand for sustainable pMDI products, aligning with new European Union F-gas legislation for phased propellant reduction by 2029.

CEO Insight on Sustainability Goals

– Milton Boyer, CEO, Kindeva: “This investment will bring to the market one of the first large-volume commercial green propellant lines… Our first GMP low-GWP manufacturing line expected to be operational in 2024, we are proud to be leading the transition to low-GWP propellants.”

Driving Sustainable Innovation

Kindeva’s investment ensures pharmaceutical companies can meet sustainability goals without compromising patient choice. With nearly 70 years in pMDIs, the company invented the technology and has consistently led major transitions, including the switch from CFC to HFA propellants in the 1990s.

Comprehensive Drug-Device Solutions

Kindeva offers early-stage feasibility through commercial scale production for drug delivery systems like pulmonary & nasal, injectable, and transdermal. Their state-of-the-art facilities in the U.S. and U.K. support their global client base.

  Kindeva Drug Delivery, low-GWP propellants, pMDI manufacturing, pressurized metered-dose inhalers, sustainable inhalers